O Dereure1, P Portales, J Clot, J J Guilhou. 1. Department of Dermatology-Phlebology and Laboratory of Immunology, University Hospital of Montpellier, Hôpital Saint-Eloi, 2 avenue B. Sans, 34295 Montpellier Cedex 5, France. ofdereure@wanadoo.fr
Abstract
BACKGROUND: The usually protracted and indolent course of cutaneous T-cell lymphoma (CTCL) is consistent with an accumulation of lymphocytes rather than being a true proliferative disorder, perhaps as the result of defective lymphocyte apoptosis. Fas (CD95) is the main signalling membrane molecule involved in postactivation T-lymphocyte apoptosis. OBJECTIVES: To evaluate expression of Fas on circulating CD4+ lymphocytes in patients with CTCL. METHODS: Fas expression on peripheral blood CD4+ T cells in 16 patients with mycosis fungoides (patch and infiltrated plaque stages) and in four patients with Sézary syndrome was compared with that in 25 matched patients with lymphocyte-mediated cutaneous benign inflammatory disorders and in 15 subjects without inflammatory cutaneous diseases. RESULTS: Fas expression on peripheral CD4+ lymphocytes was significantly lower in patients with CTCL compared with subjects with benign inflammatory cutaneous disorders and with healthy donors. CONCLUSIONS: This pattern supports the hypothesis that a defect in T-cell apoptosis may play a part in the pathophysiology of CTCL, perhaps through abnormalities of the Fas/Fas ligand system. Alternatively, this decrease could be the result of the presence of the soluble Fas ligand molecule in the sera of patients with CTCL.
BACKGROUND: The usually protracted and indolent course of cutaneous T-cell lymphoma (CTCL) is consistent with an accumulation of lymphocytes rather than being a true proliferative disorder, perhaps as the result of defective lymphocyte apoptosis. Fas (CD95) is the main signalling membrane molecule involved in postactivation T-lymphocyte apoptosis. OBJECTIVES: To evaluate expression of Fas on circulating CD4+ lymphocytes in patients with CTCL. METHODS:Fas expression on peripheral blood CD4+ T cells in 16 patients with mycosis fungoides (patch and infiltrated plaque stages) and in four patients with Sézary syndrome was compared with that in 25 matched patients with lymphocyte-mediated cutaneous benign inflammatory disorders and in 15 subjects without inflammatory cutaneous diseases. RESULTS:Fas expression on peripheral CD4+ lymphocytes was significantly lower in patients with CTCL compared with subjects with benign inflammatory cutaneous disorders and with healthy donors. CONCLUSIONS: This pattern supports the hypothesis that a defect in T-cell apoptosis may play a part in the pathophysiology of CTCL, perhaps through abnormalities of the Fas/Fas ligand system. Alternatively, this decrease could be the result of the presence of the soluble Fas ligand molecule in the sera of patients with CTCL.
Authors: Linghua Wang; Xiao Ni; Kyle R Covington; Betty Y Yang; Jessica Shiu; Xiang Zhang; Liu Xi; Qingchang Meng; Timothy Langridge; Jennifer Drummond; Lawrence A Donehower; Harshavardhan Doddapaneni; Donna M Muzny; Richard A Gibbs; David A Wheeler; Madeleine Duvic Journal: Nat Genet Date: 2015-11-09 Impact factor: 38.330
Authors: Janet Y Li; Steven Horwitz; Alison Moskowitz; Patricia L Myskowski; Melissa Pulitzer; Christiane Querfeld Journal: Cancer Manag Res Date: 2012-03-12 Impact factor: 3.989
Authors: Andrea M Moerman-Herzog; Daniel A Acheampong; Amanda G Brooks; Suzan M Blair; Ping-Ching Hsu; Henry K Wong Journal: Oncotarget Date: 2019-08-20
Authors: Laszlo Kari; Andrey Loboda; Michael Nebozhyn; Alain H Rook; Eric C Vonderheid; Calen Nichols; Dezso Virok; Celia Chang; Wen-Hwai Horng; James Johnston; Maria Wysocka; Michael K Showe; Louise C Showe Journal: J Exp Med Date: 2003-06-02 Impact factor: 14.307